FDA Halts The TIDE Of New Avandia Patients; Informed Consent Changes Loom

Agency's partial clinical hold prevents new subjects from enrolling in GlaxoSmithKline's postmarketing safety study of rosiglitazone and suggests informed consent process for current subjects be revised to reflect advisory committee deliberations on the drug's safety.